Which has better valuation & earnings, BNTX or ARGX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.04 -$1.29B -$5.88 N/A argenex $4.25B 12.58 $1.29B $22.46 38.26

Is BNTX or ARGX more profitable?

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 44.37% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% argenex 31.31% 44.37% 37.55%

Does the media favor BNTX or ARGX?

In the previous week, BioNTech had 2 more articles in the media than argenex. MarketBeat recorded 6 mentions for BioNTech and 4 mentions for argenex. BioNTech's average media sentiment score of 0.88 beat argenex's score of 0.78 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAK or BNTX?

BioNTech has a consensus price target of $129.13, suggesting a potential upside of 42.84%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 BioNTech 1 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.74

Does the media refer more to TAK or BNTX?

In the previous week, BioNTech had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for BioNTech and 1 mentions for Takeda Pharmaceutical. BioNTech's average media sentiment score of 0.88 beat Takeda Pharmaceutical's score of 0.38 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or RVMD?

In the previous week, Revolution Medicines had 1 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Revolution Medicines and 6 mentions for BioNTech. Revolution Medicines' average media sentiment score of 0.89 beat BioNTech's score of 0.88 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than BioNTech. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 6 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 1.12 beat BioNTech's score of 0.88 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 16 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ONC or BNTX?

In the previous week, BeOne Medicines and BeOne Medicines both had 6 articles in the media. BioNTech's average media sentiment score of 0.88 beat BeOne Medicines' score of 0.87 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioNTech (BNTX) Competitors

$90.40 +0.33 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$90.41 +0.01 (+0.01%)

As of 07:11 PM Eastern

Compare

BNTX vs. ARGX, TAK, RVMD, TEVA, and ONC

Should you buy BioNTech stock or one of its competitors? MarketBeat compares BioNTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNTech include argenex (ARGX), Takeda Pharmaceutical (TAK), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does BioNTech compare to argenex?

BioNTech (NASDAQ:BNTX) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.04	-$1.29B	-$5.88	N/A
argenex	$4.25B	12.58	$1.29B	$22.46	38.26

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 42.84%. argenex has a consensus target price of $1,037.61, indicating a potential upside of 20.73%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, BioNTech had 2 more articles in the media than argenex. MarketBeat recorded 6 mentions for BioNTech and 4 mentions for argenex. BioNTech's average media sentiment score of 0.88 beat argenex's score of 0.78 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 44.37% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
argenex	31.31%	44.37%	37.55%

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, argenex has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

argenex beats BioNTech on 12 of the 17 factors compared between the two stocks.

How does BioNTech compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 4.31% compared to BioNTech's net margin of -44.39%. Takeda Pharmaceutical's return on equity of 11.20% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
BioNTech	-44.39%	-5.30%	-4.62%

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

BioNTech has a consensus price target of $129.13, suggesting a potential upside of 42.84%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Takeda Pharmaceutical has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.84	-$1.01B	$0.39	42.09
BioNTech	$3.25B	7.04	-$1.29B	-$5.88	N/A

In the previous week, BioNTech had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 6 mentions for BioNTech and 1 mentions for Takeda Pharmaceutical. BioNTech's average media sentiment score of 0.88 beat Takeda Pharmaceutical's score of 0.38 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats Takeda Pharmaceutical on 10 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

BioNTech (NASDAQ:BNTX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Revolution Medicines has lower revenue, but higher earnings than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.04	-$1.29B	-$5.88	N/A
Revolution Medicines	$11.58M	3,395.91	-$1.13B	-$7.07	N/A

BioNTech currently has a consensus target price of $129.13, suggesting a potential upside of 42.84%. Revolution Medicines has a consensus target price of $144.00, suggesting a potential downside of 22.15%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Revolution Medicines	N/A	-83.22%	-59.06%

In the previous week, Revolution Medicines had 1 more articles in the media than BioNTech. MarketBeat recorded 7 mentions for Revolution Medicines and 6 mentions for BioNTech. Revolution Medicines' average media sentiment score of 0.89 beat BioNTech's score of 0.88 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

Summary

Revolution Medicines beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does BioNTech compare to Teva Pharmaceutical Industries?

BioNTech (NASDAQ:BNTX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than BioNTech. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 6 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 1.12 beat BioNTech's score of 0.88 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	16 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BioNTech's net margin of -44.39%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.04	-$1.29B	-$5.88	N/A
Teva Pharmaceutical Industries	$17.26B	2.12	$1.41B	$1.33	23.91

BioNTech presently has a consensus price target of $129.13, suggesting a potential upside of 42.84%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 31.40%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

15.5% of BioNTech shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, BeOne Medicines and BeOne Medicines both had 6 articles in the media. BioNTech's average media sentiment score of 0.88 beat BeOne Medicines' score of 0.87 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to BioNTech's net margin of -44.39%. BeOne Medicines' return on equity of 12.06% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
BioNTech	-44.39%	-5.30%	-4.62%

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

BeOne Medicines currently has a consensus target price of $390.92, suggesting a potential upside of 27.52%. BioNTech has a consensus target price of $129.13, suggesting a potential upside of 42.84%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BeOne Medicines has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.30	$286.93M	$4.47	68.58
BioNTech	$3.25B	7.04	-$1.29B	-$5.88	N/A

Summary

BeOne Medicines beats BioNTech on 9 of the 15 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.78B	$3.68B	$6.86B	$12.45B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-15.37	11.18	22.24	21.94
Price / Sales	7.04	311.16	524.25	93.49
Price / Cash	67.46	143.66	48.59	59.36
Price / Book	0.94	8.54	10.80	6.33
Net Income	-$1.29B	$23.83M	$3.59B	$331.02M
7 Day Performance	-4.13%	-3.53%	-2.24%	-1.09%
1 Month Performance	-0.15%	6.29%	3.12%	-0.49%
1 Year Performance	-18.56%	48.64%	26.30%	19.90%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	4.4069 of 5 stars	$90.40 +0.4%	$129.13 +42.8%	-20.2%	$22.78B	$3.25B	N/A	7,807
ARGX argenex	4.4943 of 5 stars	$916.80 -2.4%	$1,034.56 +12.8%	+56.4%	$58.44B	$4.25B	40.82	1,863	News Coverage
TAK Takeda Pharmaceutical	1.3678 of 5 stars	$16.91 +0.8%	N/A	+12.4%	$53.37B	$28.32B	43.35	47,000
RVMD Revolution Medicines	1.8675 of 5 stars	$189.99 +0.4%	$142.33 -25.1%	+383.8%	$40.23B	$11.58M	N/A	250
TEVA Teva Pharmaceutical Industries	4.8022 of 5 stars	$35.29 +1.9%	$41.78 +18.4%	+96.2%	$39.83B	$17.26B	26.53	33,950	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. ARGX, TAK, RVMD, TEVA, and ONC

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Takeda Pharmaceutical?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Summary

How does BioNTech compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. ARGX, TAK, RVMD, TEVA, and ONC

How does BioNTech compare to argenex?

Which has better valuation & earnings, BNTX or ARGX?

Do institutionals and insiders believe in BNTX or ARGX?

Do analysts recommend BNTX or ARGX?

Does the media favor BNTX or ARGX?

Is BNTX or ARGX more profitable?

Which has more risk & volatility, BNTX or ARGX?

Summary

How does BioNTech compare to Takeda Pharmaceutical?

Do institutionals & insiders hold more shares of TAK or BNTX?

Is TAK or BNTX more profitable?

Which has more risk & volatility, TAK or BNTX?

Do analysts rate TAK or BNTX?

Which has stronger valuation & earnings, TAK or BNTX?

Does the media refer more to TAK or BNTX?

Summary

How does BioNTech compare to Revolution Medicines?

Which has better earnings and valuation, BNTX or RVMD?

Do analysts rate BNTX or RVMD?

Do insiders & institutionals have more ownership in BNTX or RVMD?

Is BNTX or RVMD more profitable?

Does the media prefer BNTX or RVMD?

Which has more volatility & risk, BNTX or RVMD?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Does the media refer more to BNTX or TEVA?

Is BNTX or TEVA more profitable?

Which has higher earnings & valuation, BNTX or TEVA?

Do analysts recommend BNTX or TEVA?

Do insiders & institutionals have more ownership in BNTX or TEVA?

Which has more risk & volatility, BNTX or TEVA?

Summary

How does BioNTech compare to BeOne Medicines?

Does the media prefer ONC or BNTX?

Is ONC or BNTX more profitable?

Which has more volatility and risk, ONC or BNTX?

Do analysts recommend ONC or BNTX?

Do institutionals & insiders have more ownership in ONC or BNTX?

Which has preferable earnings & valuation, ONC or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools